Sarepta Therapeutics (SRPT) PT Raised to $112 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Sarepta Therapeutics (SRPT) PT Raised to $127 at Goldman Sachs; 'Multiple shots on DMD'
May 18, 2018 8:36 AM EDTGoldman Sachs raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $127.00 (from $84.00) while maintaining a Buy rating, citing multiple shots on DMD.
Analyst Salveen Richter notes they conducted a deep dive into SRPTs 25-drug muscular dystrophy pipeline, encompassing a myriad of technologies.
While the Exondys 51 launch has been... More
